Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with a lymphoma or solid tumour that has come back or has not responded to previous treatment
• People whose general physical health and ability to carry out daily activities is rated as fully active or restricted in strenuous activity only (this is measured using a standard scale called ECOG; confirm with trial site)
• People with a life expectancy of at least 3 months
• People whose organs (such as kidneys and liver) and bone marrow are functioning well enough to meet the trial's requirements (confirm with trial site)
• People who have at least one tumour that can be measured or assessed using standard imaging methods
• People who are willing and able to give written consent and follow the study requirements

Who may not be able to join:

• People who have received any anti-cancer treatment (such as chemotherapy, radiation, targeted therapy, or immunotherapy) within 4 weeks before the trial starts
• People who have previously been treated with a drug that targets proteins called CD47 or SIRPα
• People who have had major surgery within 4 weeks before the trial starts, or who are expected to have major surgery during the trial
• People who have received a live vaccine within 4 weeks before the trial starts, or who would need one during the trial
• People who have cancer that has spread to the brain or spinal cord
• People who have had a different type of cancer within the past 5 years
• People who have another serious, uncontrolled medical condition
• People who have HIV, hepatitis B, or hepatitis C infection (specific blood test results apply; confirm with trial site)
• People who have an active or suspected autoimmune disease
• Women who could become pregnant, unless they agree to use two reliable forms of contraception, or to avoid heterosexual intercourse, both during the trial and for at least 12 months after all treatment ends
• People with a known history of a condition where the body destroys its own red blood cells (haemolytic anaemia)
• People who have had a known severe allergic reaction or serious reaction to a monoclonal antibody treatment in the past

Important: Always verify eligibility with the trial site directly before applying.